VERACOLATE COMBINATION PRODUCT TABLET

Indications

• Dyslipidemia
• Cholestasis
• Biliary obstruction
• Gallstone disease

Dosage

Children: Refer to the BNF for Children for appropriate dosing, as it is dependent on age, weight, and clinical condition.

Adults: Refer to specific clinical guidelines or the BNF for appropriate dosing, as it varies based on indication and formulation.

Mechanism of action

Bile acids act by emulsifying dietary fats, increasing their surface area for the action of pancreatic lipases. This enhances the absorption of fatty acids and monoglycerides in the intestinal tract. Additionally, bile salts help in the solubilization of fat-soluble vitamins (A, D, E, K), making them more bioavailable.

Pharmacodynamics

Bile acids stimulate the secretion of bile and pancreatic enzymes and promote the intestinal absorption of lipids. They also have a role in maintaining intestinal microbiota balance and exert beneficial effects on metabolism, including cholesterol homeostasis and glucose metabolism.

Pharmacokinetics

Bile acids are reabsorbed in the ileum and returned to the liver via the portal vein in a process known as enterohepatic circulation. Their half-life varies, but they are generally recycled multiple times during digestion. The hepatic uptake and secretion of bile acids are regulated by several factors, including hormonal signals and the concentration of bile acids themselves.

Pregnancy

There is limited data on the effects of bile during pregnancy. It is advisable to consult a healthcare professional for guidance.

Breast-feeding

Consult a healthcare professional as there is limited information regarding the excretion of bile in breast milk.

Storage

Store in a cool, dry place, away from direct sunlight.

Indications

• Topical pain relief for conditions such as osteoarthritis and neuropathic pain
• Management of postherpetic neuralgia
• Supportive treatment for muscle and joint pain
• Stimulation of digestion and appetite

Dosage

Children: Dosage for pediatric patients should be determined by a healthcare provider, taking into consideration

Adults: Topical formulations generally recommend application to the affected area, with specific dosing instructions provided by the product label. For oral supplements, follow the manufacturer's guidelines or consult a healthcare professional.

Mechanism of action

Capsaicin, the main active component in Capsicum, exerts its effects by binding to the TRPV1 (transient receptor potential vanilloid 1) receptor, which is a cation channel involved in the transmission of pain and heat sensations. This binding leads to the depolarization of sensory neurons, resulting in the release of substance P, a neuropeptide associated with pain signaling. Continuous exposure to capsaicin results in the desensitization of these receptors, leading to decreased pain perception over time.

Pharmacodynamics

The analgesic properties of Capsicum are attributed to its ability to alter the perception of pain. Capsaicin induces a sensation of warmth and pain initially, which is followed by a prolonged analgesic effect due to the depletion of substance P from the nerve endings. Additionally, Capsicum may exhibit anti-inflammatory effects through the modulation of cytokine release and inhibition of inflammatory pathways, contributing to its therapeutic applications in pain management and inflammatory conditions.

Pharmacokinetics

Capsaicin is poorly absorbed when ingested orally, but it can be effectively absorbed through the skin when applied topically. After application, it is metabolized by the liver, and its metabolites are excreted primarily through the kidneys. The onset of action for topical preparations can vary, with effects often observed within hours. The duration of action may last from several hours to days, depending on the formulation and the area of application.

Adverse effects

• Burning sensation at the site of application
• Skin irritation or rash
• Gastrointestinal upset (if ingested)
• Allergic reactions

Precautions

• Avoid contact with eyes and mucous membranes
• Use caution in patients with sensitive skin
• Consult a healthcare professional before use in patients with underlying health conditions

Pregnancy

Capsicum is generally considered unsafe during pregnancy due to potential effects on the fetus. Pregnant women should consult a healthcare provider before use.

Breast-feeding

Capsicum should be used with caution during breastfeeding as it may affect milk production or flavor.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Topical ointments or creams
• Capsules
• Powdered form for oral use

Indications

• Constipation
• Bowel preparation before medical procedures

Dosage

Children: Refer to established guidelines and dosing recommendations as specific doses are not provided.

Adults: Refer to established guidelines and dosing recommendations as specific doses are not provided.

Mechanism of action

Cascara works primarily by its active constituents, such as cascarosides, which stimulate the mucosa of the colon, leading to increased peristalsis and the secretion of mucus. This action helps facilitate bowel movements and alleviates constipation. The stimulation of the colon may also enhance fluid secretion into the intestine, further assisting in stool softening and easing passage.

Pharmacodynamics

The pharmacodynamic effects of cascara are characterized by its laxative action, which is dose-dependent. At therapeutic doses, cascara promotes gastrointestinal motility and increases the frequency of bowel movements. The onset of action typically occurs within 6 to 12 hours, making it suitable for overnight relief of constipation. Chronic use may lead to dependence on laxatives for bowel function.

Pharmacokinetics

Cascara is not well absorbed in the gastrointestinal tract, and its active compounds primarily exert their effects locally within the intestines. The absorption of anthraquinones is minimal, and they undergo metabolic degradation in the liver. The elimination half-life varies but is generally short, with effects lasting until the bowel has emptied. Chronic use can lead to alterations in electrolyte balance, particularly potassium levels.

Contra-indications

• Intestinal obstruction
• Severe dehydration
• Appendicitis
• Abdominal pain of unknown origin
• Hypersensitivity to cascara or any of its components

Adverse effects

• Abdominal cramps
• Diarrhea
• Nausea
• Vomiting
• Electrolyte imbalance
• Dependency on laxatives with prolonged use

Interactions

• May reduce the effectiveness of certain medications due to altered gastrointestinal transit time
• Potentially increased risk of electrolyte disturbances when used with diuretics or other agents affecting electrolyte balance

Precautions

• Use with caution in patients with renal impairment
• Not recommended for long-term use due to potential for dependency
• Patients should be advised on adequate hydration while using cascara

Pregnancy

Cascara should be used during pregnancy only if clearly needed, as safety in pregnancy has not been established.

Breast-feeding

Cascara is not recommended during breastfeeding, as it may pass into breast milk and affect the infant.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Formulations

• Cascara sagrada bark (dried)
• Cascara liquid extract
• Cascara capsules or tablets

Indications

• Antimicrobial treatment
• Antioxidant therapy
• Flavoring agent in food
• Natural preservative
• Traditional medicine applications

Dosage

Children: Refer to specific product guidelines or consult a healthcare professional for appropriate dosing.

Adults: Refer to specific product guidelines or consult a healthcare professional for appropriate dosing.

Mechanism of action

The mechanism of action of oleoresin varies depending on its source and the specific compounds it contains. Generally, oleoresins exhibit antimicrobial activity, which may involve the disruption of microbial cell membranes or interference with metabolic processes. Additionally, some components may have anti-inflammatory and antioxidant effects, contributing to their therapeutic potential.

Pharmacodynamics

Oleoresins exhibit a range of pharmacodynamic effects, including antimicrobial, antioxidant, and anti-inflammatory activities. The specific effects will depend on the source of the oleoresin and its chemical composition. These properties are attributed to the various phytochemicals present, such as terpenes, phenolics, and other bioactive compounds, which can modulate biological pathways and influence physiological responses.

Pharmacokinetics

The pharmacokinetics of oleoresin are not well-defined due to the complexity of its composition. Generally, the absorption and metabolism of oleoresins can vary widely based on the individual compounds they contain. Lipophilic components may be absorbed through the gastrointestinal tract and metabolized in the liver, while other components may undergo different metabolic pathways. The elimination half-life is also variable, reflecting the diverse nature of its constituents.

Pregnancy

Safety in pregnancy has not been established, consult healthcare provider.

Breast-feeding

Consult healthcare provider before use during breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Constipation
• Bowel preparation prior to surgical procedures
• Occasional use for laxative effect

Dosage

Children: Refer to BNF for Children for specific pediatric dosing guidelines.

Adults: Refer to BNF for specific dosing information. Typical adult dosing for constipation may involve a single oral dose of 10 to 15 mg, taken as needed.

Mechanism of action

Phenolphthalein alters fluid and electrolyte absorption in the intestines, producing net intestinal fluid accumulation and laxative effects. It increases concentrations of cyclic 3'-5'-adenosine monophosphate (cAMP) in colonic mucosal cells, affecting cell permeability and promoting fluid accumulation. Additionally, phenolphthalein stimulates intestinal activity, particularly in the colon, approximately 6 hours after ingestion. It also inhibits water absorption in both the large and small intestines, contributing to its laxative effects.

Pharmacodynamics

Phenolphthalein acts primarily by stimulating the secretion of intestinal fluids and enhancing motility in the gastrointestinal tract. Its laxative effects are mediated by increased intestinal fluid volume and reduced water absorption. The compound may also influence prostaglandin E biosynthesis in the colon, further enhancing its action. However, the identification of hydroxyphenolphthalein (a metabolite) raises concerns about its potential toxicity and genotoxicity.

Pharmacokinetics

Phenolphthalein is absorbed after oral administration and is metabolized in the liver. Its onset of action occurs around 6 hours post-ingestion, with peak effects typically noted thereafter. The compound is primarily excreted in urine, and its pharmacokinetic profile may be influenced by individual metabolic rates and gastrointestinal transit times.

Adverse effects

• Abdominal cramps
• Diarrhea
• Nausea
• Vomiting
• Electrolyte imbalance
• Dehydration
• Potential carcinogenic effects with prolonged use

Precautions

• Use with caution in patients with renal impairment
• May cause dependence or overuse leading to chronic laxative use
• Monitor electrolyte levels during prolonged use

Pregnancy

Phenolphthalein should be avoided during pregnancy due to potential risks to the fetus, including possible carcinogenic effects.

Breast-feeding

It is not recommended to use phenolphthalein while breastfeeding due to potential risks to the infant.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Oral tablets
• Liquid formulations

Indications

• Constipation
• Bowel preparation prior to procedures
• Occasional use for digestive health

Dosage

Children: Refer to established guidelines for specific dosing recommendations, as doses may vary based on formulation and patient needs.

Adults: Refer to established guidelines for specific dosing recommendations, as doses may vary based on formulation and patient needs.

Mechanism of action

The primary mechanism of action of Sagrada involves the stimulation of the mucosal lining of the colon, leading to increased peristalsis and bowel movement. The anthraquinones present in Sagrada, such as sennosides, act as irritants to the intestinal mucosa, promoting fluid secretion and enhancing gut motility. This action results in softer stools and a more efficient bowel evacuation process.

Pharmacodynamics

Sagrada exhibits its pharmacodynamic effects through the interaction of its active compounds with the intestinal mucosa. This interaction causes an increase in intestinal motility and secretion of electrolytes and fluids into the bowel, which assists in stool formation and passage. The onset of action is typically within 6 to 12 hours when taken orally, making it suitable for use as an overnight laxative.

Pharmacokinetics

Sagrada is not extensively absorbed in the gastrointestinal tract; its effects are primarily local within the colon. The bioavailability of its active compounds is low, as they are metabolized by gut bacteria. The elimination half-life is variable, but due to its local action, significant systemic absorption and consequent pharmacokinetic profiling is minimal. It is essential to consider the potential for electrolyte imbalances with prolonged use.

Adverse effects

• Gastrointestinal upset
• Diarrhea
• Abdominal cramping
• Nausea
• Electrolyte imbalance

Interactions

• May interact with diuretics, increasing the risk of electrolyte imbalance
• Potential interaction with other laxatives, enhancing effects

Precautions

• Use with caution in patients with a history of gastrointestinal obstruction
• Monitor for signs of dehydration or electrolyte disturbances

Pregnancy

Safety during pregnancy has not been established. Use only if clearly needed.

Breast-feeding

Information about the excretion of sagrada in human milk is not available. Caution is advised when administered to breastfeeding women.

Storage

Store in a cool, dry place, away from direct sunlight and moisture.

Formulations

• Powder for oral suspension
• Tablets
• Capsules

Indications

• Electrolyte replacement
• Treatment of hyponatremia
• Management of hypokalemia
• Acid-base balance correction
• Nutritional supplementation

Dosage

Children: Refer to specific pediatric dosing references for appropriate salt formulations and dosages.

Adults: Refer to specific product information for dosing guidelines, as it varies widely depending on the type of salt and indication.

Mechanism of action

Salts exert their effects primarily through the dissociation of cations and anions in solution, which can influence osmotic balance, acid-base status, and cellular function. For example, sodium salts can increase plasma sodium levels, affecting fluid balance and nerve transmission, while potassium salts can help maintain cellular excitability and muscle contraction.

Pharmacodynamics

The pharmacodynamics of salts varies depending on the specific cation or anion involved. Electrolyte salts help maintain homeostasis by regulating the movement of water across cell membranes, influencing nerve impulse transmission, and facilitating muscle contraction. The balance of electrolytes is critical for normal physiological function, and deviations can lead to conditions such as dehydration, muscle cramps, and arrhythmias.

Pharmacokinetics

Salts are absorbed in the gastrointestinal tract, with the rate of absorption varying by the specific salt and its formulation. Once in the bloodstream, they distribute throughout the body and are utilized in various metabolic processes. Excretion typically occurs via the kidneys, with renal function playing a key role in maintaining electrolyte balance. The half-life of salts depends on the specific compound and the body’s needs for that particular electrolyte.

Contra-indications

• Hypersensitivity to the specific salt
• Severe renal impairment
• Hyperkalemia for potassium salts
• Hypernatremia for sodium salts

Adverse effects

• Gastrointestinal upset
• Nausea
• Diarrhea
• Abdominal cramps
• Electrolyte imbalance
• Cardiac arrhythmias (especially with potassium salts)

Interactions

• Potassium salts may interact with ACE inhibitors, potassium-sparing diuretics, and certain non-steroidal anti-inflammatory drugs (NSAIDs)
• Sodium salts may interact with diuretics and corticosteroids, affecting fluid and electrolyte balance

Precautions

• Use with caution in patients with cardiovascular disease
• Monitor electrolyte levels regularly in patients receiving large doses
• Assess renal function before initiating therapy

Pregnancy

Consult with a healthcare provider. Some salts may be used, but caution is advised due to potential effects on electrolyte balance.

Breast-feeding

Consult with a healthcare provider. Most salts are considered safe, but monitoring for any adverse effects in the infant is recommended.

Storage

Store in a cool, dry place, away from light. Ensure containers are tightly closed.

Formulations

• Oral tablets
• Oral solutions
• Powder for reconstitution
• Intravenous solutions

Mechanism of action

Stimulant drugs alter fluid and electrolyte absorption, producing net intestinal fluid accumulation and laxation. Increased concentrations of cyclic 3'-5'-adenosine monophosphate (CAMP) occurring in clonic mucosal cells may alter the permeability of these cells leading to net fluid accumulation and laxative action. Phenolphthalein also acts directly or reflexly to increase the the activity of the small intestine. Phenolphthalein acts mainly on the colon about 6 hours after ingestion. When taken orally, it is thought to be dissolved by intestinal juices and bile and to stimulate intestinal musculature, chiefly that of colon. Phenolphthalein increased intestinal fluid volume in rat colon in situ, apparently via stimulation of prostaglandin E biosynthesis in colon. Water absorption from intestines of 6 pt with ileostomies and from rats was measured after administration of phenolphthalein. Results indicate that some laxative effects result from inhibition of water absorption in large and small intestines. .... A catechol metabolite of PT, hydroxyphenolphthalein (PT-CAT), was recently identified and may be the molecular species responsible for at least part of the toxicity/carcinogenicity of PT. We hypothesize that PT-CAT inhibits the enzyme catechol-O-methyltransferase (COMT) and therefore potentiates genotoxicity by either PT-CAT itself or the endogenous catechol estrogens (CEs) in susceptible tissues. The present studies were conducted to determine the effects of PT treatment and PT-CAT itself on the COMT-mediated metabolism of 4- and 2-hydroxyestradiol both in vitro and in vivo. Female mice were treated with PT (50 mg/kg/d) for 21 days and then euthanized. PT-CAT concentration in urine reached plateau levels by 7 days of exposure. An O-methylated metabolite of PT-CAT was detected in feces. In vitro experiments demonstrated that PT treatment resulted in an increase in free CEs, which are normally cleared by COMT and a concurrent decrease in the capacity of hepatic catechol clearance by COMT. In vitro, PT-CAT was a substrate of COMT, with kinetic properties within the range measured with endogenous substrates. PT-CAT was an extremely potent mixed-type inhibitor of the O-methylation of the catechol estrogens, with 90-300 nM IC50s.